RetiSpec
Noninvasive Eye Scan to Detect Alzheimer's Disease
Company Overview
Snapshot
Founded in June 2016 by Roy Kirshon, RetiSpec operates with 11–50 employees. The company has raised $13.55 million across 4 funding rounds from 4 investors. In July 2024, RetiSpec closed a $10 million funding round to advance the commercialization of its AI-driven eye test for Alzheimer's disease detection.
Business overview
RetiSpec is a medical imaging company focused on the early detection of Alzheimer's disease biomarkers. The company's core technology utilizes hyperspectral imagery in synergy with machine learning and computer vision algorithms to identify Alzheimer's biomarkers through a quick, non-invasive eye exam. This approach aims to enable widespread, accessible, and scalable screening, providing a window for timely therapeutic interventions. RetiSpec operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Digital Medical Diagnostics, serving healthcare providers.
Strategic signal
In July 2024, RetiSpec secured $10 million to accelerate the commercialization of its AI-driven eye test for Alzheimer's disease. This significant capital infusion signals strong investor confidence in the company's technology and its potential to revolutionize early detection methods for Alzheimer's, paving the way for broader market adoption and impact on patient care.
Company Intelligence Q&A
- What was the most recent funding event for RetiSpec?
- In July 2024, RetiSpec closed a $10 million funding round. This round was led by iGan Partners and joined by Gentex Corporation.
- When was RetiSpec founded and by whom?
- RetiSpec was founded in June 2016 by Roy Kirshon.
- What is RetiSpec's primary focus in the medical field?
- RetiSpec is a medical imaging company developing a tool for the early detection of Alzheimer's disease biomarkers in the eye, aiming to enable widespread early detection through accessible and scalable screening.
- Which organizations collaborated with RetiSpec on an early detection program for Alzheimer's?
- In May 2022, RetiSpec and Toronto Memory Program were awarded a grant to launch an innovative early detection program for Alzheimer's in Toronto, Canada.
- What technology does RetiSpec use for biomarker identification?
- RetiSpec's patented technology harnesses hyperspectral imagery in synergy with machine learning and computer vision algorithms to allow for rapid, simple, and cost-effective identification of Alzheimer's biomarkers.